134 results for «100»

Filter By

134 results

EuroPCR 2021 - Unprecedented global outreach and online interactivity during an innovative livestreamed edition

25 May 2021

Paris, France. 21 May 2021.  Since 1989, EuroPCR has constantly pioneered innovative educational tools and formats to help the interventional cardiovascular community effectively share their knowledge, skills and practice. Rising up to the challenge of the pandemic, the 31st annual edition was fundamentally rethought, reshaped and...

EuroPCR 2021

EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)

17 May 2023

Vascular robotics: Robocath unveils survey findings on users’ current expectations and future developments

15 May 2024

Large-bore mechanical thrombectomy vs catheter-directed thrombolysis for treatment of intermediate-risk pulmonary embolism: primary outcomes from the PEERLESS randomized controlled trial

30 Oct 2024

Elad Asher provides his take on the PEERLESS trial presented by Wissam A. Jaber at TCT 2024 in Washington.

Elad Asher

Author

Elad Asher
Large-bore mechanical thrombectomy vs catheter-directed thrombolysis for treatment of intermediate-risk pulmonary embolism

TRISCEND: six-month outcomes of transfemoral tricuspid valve replacement in patients with TR - a written review

09 Nov 2021

 

The 6-month follow-up of the TRISCEND study was presented during the TCT Congress 2021 by principal investigator Susheel Kodali. Alessandro Sticchi & Jonathan Curio offer a review of this trial.

Alessandro Sticchi

Author

Alessandro Sticchi
Jonathan Curio

Author

Jonathan Curio
TRISCEND Study: six-month outcomes of transfemoral tricuspid valve replacement in patients with tricuspid regurgitation

BIOTRONIK Sets New Clinical Benchmark with Ultrathin Strut Orsiro Coronary Drug-Eluting Stent

28 Feb 2022

BIOTRONIK's New Absorbable Magnesium Scaffold Achieves Major Milestone in BIOMAG-I Clinical Trial

01 Mar 2022

Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One

12 Jan 2022

LIMES Randomised Controlled Trial about Sirolimus Coated Balloon in BTK takes the first Stride: patient enrolment started

29 Jul 2022

One-year results from the FUTURE-II trial

18 May 2021

A decade already passed from the first use of bioresorbable vascular scaffold in percutaneous coronary interventions. The first studies - by using surrogate endpoints - showed some superiority of BRS vs. metallic drug-eluting stent in terms of the so-called vascular restoration therapy with recovery of vasomotion...

One-year results from the FUTURE-II trial

Successful Stent-less Percutaneous Coronary Intervention of Chronic Total Occlusion by Ablation Devices in a Young Adult

04 Nov 2021

View this case with a 38-year-old male with effort angina and chronic total occlusion at the ostial segment of the left anterior descending artery.

Successful Stent-less Percutaneous Coronary Intervention of Chronic Total Occlusion by Ablation Devices in a Young Adult

COVID-19: safety and efficacy of the mRNA-1273 SARSCoV-2 vaccine (Moderna) against SARS-CoV-2

22 Jan 2021

Examination of the study methodology and results according to the PICOT principle, SWOT analysis and real-world applicability

COVID-19: safety and efficacy of the Moderna vaccine

Disrupt CAD III: Safety and effectiveness of intravascular lithotripsy for treatment of severe coronary calcification

17 Oct 2020

At TCT Connect 2020, Dean Kereiakes presented the results of the Disrupt CAD III trial. Giuseppe Di Gioia and Dejan Milasinovic provide a summary of the key messages.

Giuseppe Di Gioia

Author

Giuseppe Di Gioia
Dejan Milasinovic

Author

Dejan Milasinovic
Live from TCT Connect 2020: The Disrupt CAD III trial

EuroPCR 2019 Press Release: A pragmatic approach to defining high bleeding risk for patients undergoing in PCI

22 May 2019

Paris, France, 22 May 2019. Identification and management of patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) is of major importance, but a lack of standardisation in defining this population limits trial design, data interpretation, and clinical decision-making.

A pragmatic approach to defining high bleeding risk for patients undergoing in PCI

ACC 2019 Day 3: SAFARI-STEMI, STOPDAPT-2, SMART-CHOICE and more

19 Mar 2019

Mirvat Al Asnag reported live on major late-breaking trials presented at ACC 2019 in New Orleans: SAFARI-STEMI, STOPDAPT-2, SMART-CHOICE, TREAT and more

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
ACC 2019 Day 3: SAFARI-STEMI, STOPDAPT-2, SMART-CHOICE and more

EXCEL: 5-year outcomes from a randomized trial of PCI vs. CABG in patients with left main coronary artery disease

01 Oct 2019

At TCT 2019 in San Francisco - USA, Gregg W. Stone presented the results of the EXCEL trial. Read the summary and analysis provided by Luis Ortega-Paz.

Luis Ortega-Paz

Author

Luis Ortega-Paz
EXCEL: 5-year outcomes from a randomized trial of PCI vs. CABG in patients with left main coronary artery disease

BIOTRONIK announces its latest innovation: Oscar multifunctional peripheral catheter

14 Feb 2023

ECLS-SHOCK: venoarterial membrane oxygenation in cardiogenic shock

27 Aug 2023

Panos Xaplanteris & Leonidas Koliastasis provide their take on the final results of the ECLS-SHOCK (Extracorporeal Life Support in Infarct-Related Cardiogenic Shock) which were presented by Holger Thiele during the ESC 2023 congress in Amsterdam.

Panagiotis Xaplanteris

Author

Panagiotis Xaplanteris

Author

Leonidas Koliastasis
ECLS-SHOCK

Elixir Medical To Announce Late-Breaking Clinical Data at EuroPCR 2023 Session Featuring World’s First Transforming Coronary Artery Implant Designed to Restore Vessel Physiology and Function

09 May 2023

FIRE1 raises $25M to revolutionize heart failure home monitoring

15 Mar 2023

Didn’t find what you were looking for?